Submission for OMB Review; Comment Request, 8878-8879 [2012-3476]
Download as PDF
<![CDATA[
8878
Federal Register / Vol. 77, No. 31 / Wednesday, February 15, 2012 / Notices
room accommodates approximately 240
people.
Security Considerations: Due to
increased security requirements CMS
has instituted stringent procedures for
entrance into the building by nongovernment employees. Attendees will
need to present valid government-issued
picture identification, and sign-in at the
security desk upon entering the
building. Attendees who wish to attend
the ICD–9–CM C&M meeting on March
5, 2012, must submit their name and
organization by February 27, 2012, for
inclusion on the visitor list. This visitor
list will be maintained at the front desk
of the CMS building and used by the
guards to admit visitors to the meeting.
Participants who attended previous
ICD–9–CM C&M meetings will no longer
be automatically added to the visitor
list. You must request inclusion of your
name prior to each meeting you attend.
Please register to attend the meeting
on-line at: https://www.cms.hhs.gov/
apps/events/.
Please contact Mady Hue (410–786–
4510 or Marilu.hue@cms.hhs.gov), for
questions about the registration process.
Purpose: The ICD–9–CM Coordination
and Maintenance Committee is a public
forum for the presentation of proposed
modifications to the International
Classification of Diseases, NinthRevision, Clinical Modification.
Matters to be Discussed: Tentative
agenda items include:
March 5, 2012
ICD–9–CM Procedure Topics:
Administration of Fidaxomicin
Placement of Modeling Catheter in
Endovascular Graft Procedure
Injection or Infusion of Glucarpidase
ICD–10 Updates:
ICD–10 MS–DRG Update
ICD–10 HAC Translation List
Impact of ICD–10 MS–DRGs
Implementation
ICD–10–CM Diagnosis Topics:
Atypical femoral fracture
Choking ‘‘game’’
Cognitive sequelae of cerebrovascular
disease
Family history of SIDS
sroberts on DSK5SPTVN1PROD with NOTICES
Addenda
Agenda items are subject to change as
priorities dictate.
Note: CMS and NCHS will no longer
provide paper copies of handouts for the
meeting. Electronic copies of all meeting
materials will be posted on the CMS and
NCHS Web sites prior to the meeting at
https://www.cms.hhs.gov/
ICD9ProviderDiagnosticCodes/03_
meetings.asp#TopOfPage and https://
www.cdc.gov/nchs/icd/icd9cm_
maintenance.htm.
VerDate Mar<15>2010
17:09 Feb 14, 2012
Jkt 226001
Contact Persons for Additional
Information: Donna Pickett, Medical
Systems Administrator, Classifications
and Public Health Data Standards Staff,
NCHS, 3311 Toledo Road, Room 2337,
Hyattsville, Maryland 20782, email
dfp4@cdc.gov, telephone 301–458–4434
(diagnosis); Mady Hue, Health
Insurance Specialist, Division of Acute
Care, CMS, 7500 Security Boulevard,
Baltimore, Maryland 21244, email
marilu.hue@cms.hhs.gov, telephone
410–786–4510 (procedures).
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities, for both the
Centers for Disease Control and
Prevention, and the Agency for Toxic
Substances and Disease Registry.
Dated: February 8, 2012.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. 2012–3484 Filed 2–14–12; 8:45 am]
BILLING CODE 4163–18–P
Centers for Disease Control and
Prevention
Advisory Committee on Immunization
Practices (ACIP)
Correction
This notice was published in the
Federal Register on February 1, 2012,
Volume 77, Number 21, Page 5026. The
matters to be discussed and times
should read as follows:
Matters To Be Discussed: The agenda
will include discussions on:
meningococcal vaccine, hepatitis B
vaccine, tetanus, diphtheria, and
acellular pertussis (Tdap) vaccine,
influenza, vaccine supply, 13-valent
pneumococcal conjugate vaccine, and
measles-mumps-rubella (MMR) vaccine.
Recommendation vote is scheduled for
Tdap vaccine. Time will be available for
public comment.
Agenda items are subject to change as
priorities dictate.
Times and Dates:
8 a.m.–5 p.m., February 22, 2012.
8 a.m.–12:30 p.m., February 23, 2012.
The Meeting is Web cast live via the
World Wide Web; for instructions and
more information on ACIP please visit
the ACIP Web site: https://www.cdc.gov/
vaccines/recs/acip/.
Contact Person for More Information:
Stephanie B. Thomas, National Center
Frm 00078
Fmt 4703
Dated: February 8, 2012.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. 2012–3481 Filed 2–14–12; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Administration for Children and
Families
Submission for OMB Review;
Comment Request
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
PO 00000
for Immunization and Respiratory
Diseases, CDC, 1600 Clifton Road NE.,
MS–A27, Atlanta, Georgia 30333,
telephone: (404)639–8836; Email
ACIP@CDC.GOV.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities for both the
Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Sfmt 4703
Title: Tracking of Participants in the
Head Start Impact Study.
OMB No.: 0970–0229.
Description: The Administration for
Children and Families (ACF) within the
Department of Health and Human
Services (HHS) will collect follow-up
information from children and families
in the Head Start Impact Study. In
anticipation of conducting a future
follow-up for the study, ACF will collect
information necessary to identify
respondents’ current location and
follow-up with respondents in the
future.
The Head Start Impact Study is a
longitudinal study involving 4,667 first
time enrolled three- and four-year-old
preschool children across 84 nationally
representative grantee/delegate
agencies. Participants have been
randomly assigned to either a Head Start
group or a control group. Data collection
for the study began in fall of 2002 and
has been extended through late spring
2008 to include the participants’ 3rd
grade year. Tracking of the participants
has continued every spring beginning in
2009 and ending in 2011.
ACF will continue to examine
outcomes for the sample through the
spring of the participant’s 12th grade
year. To maintain adequate sample size,
telephone interviews will be conducted
in order to update the respondent’s
location and contact information. This
information will be collected from
E:\FR\FM\15FEN1.SGM
15FEN1
Federal Register / Vol. 77, No. 31 / Wednesday, February 15, 2012 / Notices
parents or guardians in the spring of
2012, 2013, 2014 2015, and 2016. This
request package covers three years of
information collection, from 2012 to
2014.
Respondents: The original sample of
4,667 treatment and control group
8879
members in the Head Start Impact
Study, minus 432 families that have
refused to participate in the study.
ANNUAL BURDEN ESTIMATES
Instrument
Annual
number of
respondents
Number of
responses per
respondent
Average
burden hours
per response
Total annual
burden hours
Parent Tracking Interview ................................................................................
4235
1
13
⁄
1412
Estimated Total Annual Burden
Hours: 1412.
Additional Information: Copies of the
proposed collection may be obtained by
writing to the Administration for
Children and Families, Office of
Planning, Research and Evaluation, 370
L’Enfant Promenade SW., Washington,
DC 20447, Attn: OPRE Reports
Clearance Officer. All requests should
be identified by the title of the
information collection. Email address:
OPREinfocollection@acf.hhs.gov.
OMB Comment: OMB is required to
make a decision concerning the
collection of information between 30
and 60 days after publication of this
document in the Federal Register.
Therefore, a comment is best assured of
having its full effect if OMB receives it
within 30 days of publication. Written
comments and recommendations for the
proposed information collection should
be sent directly to the following: Office
of Management and Budget, Paperwork
Reduction Project, Fax: 202–395–6974,
Attn: Desk Officer for the
Administration for Children and
Families.
Dated: February 9, 2012.
Steven M. Hanmer,
OPRE Reports Clearance Officer.
[FR Doc. 2012–3476 Filed 2–14–12; 8:45 am]
BILLING CODE 4184–22–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
sroberts on DSK5SPTVN1PROD with NOTICES
[Docket No. FDA–2012–N–0115]
Agency Information Collection
Activities; Proposed Collection;
Comment Request: Guidance for
Industry and Food and Drug
Administration Staff; Class II Special
Controls Guidance Document:
Automated Blood Cell Separator
Device Operating by Centrifugal or
Filtration Separation Principle
AGENCY:
Food and Drug Administration,
HHS.
VerDate Mar<15>2010
17:09 Feb 14, 2012
Jkt 226001
ACTION:
Notice.
The Food and Drug
Administration (FDA) is announcing an
opportunity for public comment on the
proposed collection of certain
information by the Agency. Under the
Paperwork Reduction Act of 1995 (the
PRA), Federal Agencies are required to
publish notice in the Federal Register
concerning each proposed collection of
information, including each proposed
extension of an existing collection of
information, and to allow 60 days for
public comment in response to the
notice. This notice solicits comments on
the collection of information concerning
class II special controls for an
automated blood cell separator device
operating by centrifugal or filtration
separation principle.
DATES: Submit either electronic or
written comments on the collection of
information by April 16, 2012.
ADDRESSES: Submit electronic
comments on the collection of
information to https://
www.regulations.gov. Submit written
comments on the collection of
information to the Division of Dockets
Management (HFA–305), Food and Drug
Administration, 5630 Fishers Lane, Rm.
1061, Rockville, MD 20852. All
comments should be identified with the
docket number found in brackets in the
heading of this document.
FOR FURTHER INFORMATION CONTACT: Ila
S. Mizrachi, Office of Information
Management, Food and Drug
Administration, 1350 Piccard Dr., PI50–
400B, Rockville, MD 20850, 301–796–
7726, Ila.Mizrachi@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: Under the
PRA (44 U.S.C. 3501–3520), Federal
Agencies must obtain approval from the
Office of Management and Budget
(OMB) for each collection of
information they conduct or sponsor.
‘‘Collection of information’’ is defined
in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes Agency requests
or requirements that members of the
public submit reports, keep records, or
provide information to a third party.
Section 3506(c)(2)(A) of the PRA (44
SUMMARY:
PO 00000
Frm 00079
Fmt 4703
Sfmt 4703
U.S.C. 3506(c)(2)(A)) requires Federal
Agencies to provide a 60-day notice in
the Federal Register concerning each
proposed collection of information,
including each proposed extension of an
existing collection of information,
before submitting the collection to OMB
for approval. To comply with this
requirement, FDA is publishing notice
of the proposed collection of
information set forth in this document.
With respect to the following
collection of information, FDA invites
comments on these topics: (1) Whether
the proposed collection of information
is necessary for the proper performance
of FDA’s functions, including whether
the information will have practical
utility; (2) the accuracy of FDA’s
estimate of the burden of the proposed
collection of information, including the
validity of the methodology and
assumptions used; (3) ways to enhance
the quality, utility, and clarity of the
information to be collected; and (4)
ways to minimize the burden of the
collection of information on
respondents, including through the use
of automated collection techniques,
when appropriate, and other forms of
information technology.
Guidance for Industry and Food and
Drug Administration Staff; Class II
Special Controls Guidance Document:
Automated Blood Cell Separator Device
Operating by Centrifugal or Filtration
Separation Principle (OMB Control
Number 0910–0594)—Extension
Under the Safe Medical Devices Act
of 1990 (Pub. L. 101–629), FDA may
establish special controls, including
performance standards, postmarket
surveillance, patient registries,
guidelines, and other appropriate
actions it believes necessary to provide
reasonable assurance of the safety and
effectiveness of the device.
The special control guidance serves to
support the reclassification from class
III to class II of the automated blood cell
separator device operating on a
centrifugal separation principle
intended for the routine collection of
blood and blood components as well as
E:\FR\FM\15FEN1.SGM
15FEN1
]]>Agencies
[Federal Register Volume 77, Number 31 (Wednesday, February 15, 2012)]
[Notices]
[Pages 8878-8879]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-3476]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Administration for Children and Families
Submission for OMB Review; Comment Request
Title: Tracking of Participants in the Head Start Impact Study.
OMB No.: 0970-0229.
Description: The Administration for Children and Families (ACF)
within the Department of Health and Human Services (HHS) will collect
follow-up information from children and families in the Head Start
Impact Study. In anticipation of conducting a future follow-up for the
study, ACF will collect information necessary to identify respondents'
current location and follow-up with respondents in the future.
The Head Start Impact Study is a longitudinal study involving 4,667
first time enrolled three- and four-year-old preschool children across
84 nationally representative grantee/delegate agencies. Participants
have been randomly assigned to either a Head Start group or a control
group. Data collection for the study began in fall of 2002 and has been
extended through late spring 2008 to include the participants' 3rd
grade year. Tracking of the participants has continued every spring
beginning in 2009 and ending in 2011.
ACF will continue to examine outcomes for the sample through the
spring of the participant's 12th grade year. To maintain adequate
sample size, telephone interviews will be conducted in order to update
the respondent's location and contact information. This information
will be collected from
[[Page 8879]]
parents or guardians in the spring of 2012, 2013, 2014 2015, and 2016.
This request package covers three years of information collection, from
2012 to 2014.
Respondents: The original sample of 4,667 treatment and control
group members in the Head Start Impact Study, minus 432 families that
have refused to participate in the study.
Annual Burden Estimates
----------------------------------------------------------------------------------------------------------------
Number of Average burden
Instrument Annual number responses per hours per Total annual
of respondents respondent response burden hours
----------------------------------------------------------------------------------------------------------------
Parent Tracking Interview................... 4235 1 \1/3\ 1412
----------------------------------------------------------------------------------------------------------------
Estimated Total Annual Burden Hours: 1412.
Additional Information: Copies of the proposed collection may be
obtained by writing to the Administration for Children and Families,
Office of Planning, Research and Evaluation, 370 L'Enfant Promenade
SW., Washington, DC 20447, Attn: OPRE Reports Clearance Officer. All
requests should be identified by the title of the information
collection. Email address: OPREinfocollection@acf.hhs.gov.
OMB Comment: OMB is required to make a decision concerning the
collection of information between 30 and 60 days after publication of
this document in the Federal Register. Therefore, a comment is best
assured of having its full effect if OMB receives it within 30 days of
publication. Written comments and recommendations for the proposed
information collection should be sent directly to the following: Office
of Management and Budget, Paperwork Reduction Project, Fax: 202-395-
6974, Attn: Desk Officer for the Administration for Children and
Families.
Dated: February 9, 2012.
Steven M. Hanmer,
OPRE Reports Clearance Officer.
[FR Doc. 2012-3476 Filed 2-14-12; 8:45 am]
BILLING CODE 4184-22-M
